SPOTLIGHT: Here comes the $100B barrier
A recent conference in Philadelphia included some bold projections for biotech as the industry approaches the $100 billion mark for collective revenue. That's up from $10 billion in 1998. Keith Brownlie from Ernst & Young also notes that we're well past the point where Amgen and Genentech dominated the biotech field. Other companies like Celgene and ImClone have made an impact and more biotechs are expected to join the ranks of the Big Leagues in coming years. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
